Fig. 2.

Annualised exacerbation rates during the follow-up period, with patients categorised by exacerbation history and eosinophil count: A in the LABA/LAMA fixed-dose combination group; B in the triple therapy group. Group 1: 0–1 non-hospitalised and 0 hospitalised exacerbations in the year prior to entry and > 300 eosinophils/µL at baseline; Group 2: ≥2 non-hospitalised or ≥ 1 hospitalised exacerbations in the year prior to entry and > 300 eosinophils/µL at baseline; Group 3: 0–1 non-hospitalised and 0 hospitalised exacerbations in the year prior to entry and < 100 eosinophils/µL at baseline; Group 4: ≥2 non-hospitalised or ≥ 1 hospitalised exacerbations in the year prior to entry and < 100 eosinophils/µL at baseline